On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December 1, 2010 and must pay Haemonetics a 10% royalty on ALYX consumable net sales from January 30, 2009 until December 1, 2010 when the injunction takes effect. In addition, the court awarded pre-judgment interest at 5% on the unpaid damages awarded. These rulings may be appealed by Fenwal and/or Baxter.
Brian Concannon, Haemonetics’ president and chief executive officer said, This lawsuit was necessary to protect our Company’s intellectual property. Haemonetics remains dedicated to serving the blood collection industry and working with customers to deliver blood management solutions to improve patient care and reduce healthcare costs. We are prepared to support customers through this transition period.
